The regional treatment of liver metastases from breast cancer

✍ Scribed by Dr. Schlomo Schneebaum; Michael J. Walker; Donn Young; William B. Farrar; John P. Minton

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 609 KB
• Volume: 55
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930550108

✦ Synopsis

To determine the effect of aggressive regional therapy for liver metastasis from breast cancer, we retrospectively reviewed data on 74 patients identified with liver metastases. Forty had only liver metastases. In this group of 40 patients, 18 were treated with regional therapy only, i.e., surgical resection and/or regional chemotherapy via hepatic artery or portal vein catheters whereas 22 patients had systemic chemotherapy. The two groups were comparable. The regional chemotherapy regimen was 5-W, Adriamycin, methotrexate, and cytoxan. Median survival (27 months) for those patients treated with regional therapy (N = 18) was significantly longer than for those (N = 22) treated with systemic therapy (5 months) (P = 0.001). Only 45% of the regional treatment group failed in the liver. Our data, although retrospective and selective, suggest that certain subgroups of breast cancer patients with metastatic liver disease may benefit from aggressive regional therapy.